| Literature DB >> 35599283 |
Maira da Costa Cacemiro1, Juçara Gastaldi Cominal2, Luiz Miguel Pereira2, Maria Gabriela Berzoti-Coelho2, Giovana Michelassi Berbel2, Luciana Baroni2, Tathiane Malta2, Raquel Tognon3, Natalia de Souza Nunes2, Elizabeth Xisto Souto4, Lorena Lobo de Figueiredo-Pontes5, Ana Patricia Yatsuda2, Fabíola Attié de Castro6.
Abstract
Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation of precursor and mature myeloid cells. MPN patients may present driver mutations in JAK2, MPL, and CALR genes, which are essential to describe the molecular mechanisms of MPN pathogenesis. Despite all the new knowledge on MPN pathogenesis, many questions remain to be answered to develop effective therapies to cure MPN or impair its progression to acute myeloid leukemia. The present study examined the expression levels of the Hippo signaling pathway members in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), as well as the role that they play in disease pathogenesis. The Hippo pathway is a tumor suppressor pathway that participates in the regulation of cell proliferation, differentiation, and death. Our main finding was that the expression of tumor suppressor genes from Hippo pathway were downregulated and seemed to be associated with cell resistance to apoptosis and increased proliferation rate. Therefore, the decreased expression of Hippo pathway-related genes may contribute to the malignant phenotype, apoptosis resistance, and cell proliferation in MPN pathogenesis.Entities:
Keywords: Apoptosis; Cell proliferation; Hippo signaling pathway; LATS2; Myeloproliferative neoplasms
Mesh:
Substances:
Year: 2022 PMID: 35599283 DOI: 10.1007/s12032-022-01696-x
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064